Sun Pharmaceutical (SUNPHARMA) — Announcement

📢 Key Event
Philogen resubmitted Nidlegy™ MAA to EMA for melanoma treatment

Sun Pharmaceutical announced that its partner Philogen resubmitted the Nidlegy™ Marketing Authorization Application to the EMA for neoadjuvant melanoma treatment, incorporating longer follow-up data from the PIVOTAL Phase III study and additional safety/efficacy analyses. The resubmission addresses prior regulatory questions with enhanced Chemistry, Manufacturing, and Controls information, potentially accelerating approval timelines for this novel skin cancer therapy.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"When does Sun Pharma expect EMA approval decision on Nidlegy?" "What revenue share does Sun Pharma have from Nidlegy in Europe?" "How does Nidlegy's safety profile compare to existing melanoma treatments?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 27 July 2026

FAIRCHEMOR Fairchem Organics Limited Financial Results MPHASIS MphasiS Limited Insider Trading NTPC NTPC Limited Corporate Action CCL CCL Products (India) Limited Corporate Action ITI ITI Limited Announcement SHRIRAMFIN Shriram Finance Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.